Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial
Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A one day to four week placebo lead-in phase was foll...
Gespeichert in:
| Veröffentlicht in: | The American journal of medicine 1983-10, Vol.75 (4), p.87-94 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 4 |
| container_start_page | 87 |
| container_title | The American journal of medicine |
| container_volume | 75 |
| creator | Wallin, J.David Wilson, Daniel Winer, Nathaniel Maronde, Robert F. Michelson, Eric L. Langford, Herbert Maloy, James Poland, Marcia |
| description | Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A one day to four week placebo lead-in phase was followed by a one- to six-week titration period and a one-year maintenance period. Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels. Moreover, after six months and one year of treatment, respectively, labetalol caused a significantly (p |
| doi_str_mv | 10.1016/0002-9343(83)90140-7 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmed_primary_6356903</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002934383901407</els_id><sourcerecordid>0002934383901407</sourcerecordid><originalsourceid>FETCH-LOGICAL-e261t-ca206d4a9a50ff6b0705e0122c6481861c4400fb7c1d2fdb4c039fb7590b67593</originalsourceid><addsrcrecordid>eNo9UdtKxDAQDaLoevkDhTwqbHXStOnWB0HEGywIsj6HNJm6kbQpSVbZv_CT7briywwz53BmOIeQUwaXDJi4AoA8q3nBz2f8ogZWQFbtkAkryzKrmMh3yeSfckAOY_wYR6hLsU_2BS9FDXxCvhcBVeqwT9S3NOInBqTL9YAhYR-t7-mXTUvqVINJOe-o9t2gAprtvsO0XDvjB0VVb2i7Cj5iZw1e01eMK5fiRlZR5_v3LGHoptT4VeMwa5ztzZR2I8fq8TwGmoJV7pjstcpFPPnrR-Tt4X5x95TNXx6f727nGeaCpUyrHIQpVK1KaFvRQAUlAstzLYoZmwmmiwKgbSrNTN6aptDA63Esa2jEWPkROdvqDqumQyOHYDsV1vLPmRG_2eI4PvFpMcioLfYajQ2okzTeSgZyk4Tc2Cw3NssZl79JyIr_AL9yfM0</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wallin, J.David ; Wilson, Daniel ; Winer, Nathaniel ; Maronde, Robert F. ; Michelson, Eric L. ; Langford, Herbert ; Maloy, James ; Poland, Marcia</creator><creatorcontrib>Wallin, J.David ; Wilson, Daniel ; Winer, Nathaniel ; Maronde, Robert F. ; Michelson, Eric L. ; Langford, Herbert ; Maloy, James ; Poland, Marcia</creatorcontrib><description>Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A one day to four week placebo lead-in phase was followed by a one- to six-week titration period and a one-year maintenance period. Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels. Moreover, after six months and one year of treatment, respectively, labetalol caused a significantly (p <0.05) greater reduction in the systolic blood pressure than the methyldopa regimen. The antihypertensive effect of labetalol was associated with small, yet significant reductions in heart rate; in contrast, resting tachycardia was observed in methyldopa-treated patients. Side effect profiles of the two treatments were different, with nausea being the most commonly reported side effect during labetalol therapy, and asthenia, somnolence, and dry mouth during methyldopa therapy. Overall, 33 of 65 (53 percent) labetalol-treated and 28 of 60 (47 percent) methyldopa-treated patients had at least a good response (that is, standing diastolic blood pressure 90 to 94 mm Hg) to therapy, including 26 (40 percent) and 22 (37 percent) patients, respectively, who had standing diastolic blood pressure levels of less than 90 mm Hg. Thus, labetalol is a potentially safe and effective agent in the long-term management of the patient with severe hypertension.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/0002-9343(83)90140-7</identifier><identifier>PMID: 6356903</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Blood Pressure ; Clinical Trials as Topic ; Double-Blind Method ; Drug Therapy, Combination ; Ethanolamines - administration & dosage ; Female ; Furosemide - administration & dosage ; Humans ; Hypertension - diagnosis ; Hypertension - drug therapy ; Labetalol - administration & dosage ; Labetalol - adverse effects ; Male ; Methyldopa - administration & dosage ; Methyldopa - adverse effects ; Middle Aged</subject><ispartof>The American journal of medicine, 1983-10, Vol.75 (4), p.87-94</ispartof><rights>1983</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0002934383901407$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6356903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wallin, J.David</creatorcontrib><creatorcontrib>Wilson, Daniel</creatorcontrib><creatorcontrib>Winer, Nathaniel</creatorcontrib><creatorcontrib>Maronde, Robert F.</creatorcontrib><creatorcontrib>Michelson, Eric L.</creatorcontrib><creatorcontrib>Langford, Herbert</creatorcontrib><creatorcontrib>Maloy, James</creatorcontrib><creatorcontrib>Poland, Marcia</creatorcontrib><title>Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A one day to four week placebo lead-in phase was followed by a one- to six-week titration period and a one-year maintenance period. Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels. Moreover, after six months and one year of treatment, respectively, labetalol caused a significantly (p <0.05) greater reduction in the systolic blood pressure than the methyldopa regimen. The antihypertensive effect of labetalol was associated with small, yet significant reductions in heart rate; in contrast, resting tachycardia was observed in methyldopa-treated patients. Side effect profiles of the two treatments were different, with nausea being the most commonly reported side effect during labetalol therapy, and asthenia, somnolence, and dry mouth during methyldopa therapy. Overall, 33 of 65 (53 percent) labetalol-treated and 28 of 60 (47 percent) methyldopa-treated patients had at least a good response (that is, standing diastolic blood pressure 90 to 94 mm Hg) to therapy, including 26 (40 percent) and 22 (37 percent) patients, respectively, who had standing diastolic blood pressure levels of less than 90 mm Hg. Thus, labetalol is a potentially safe and effective agent in the long-term management of the patient with severe hypertension.</description><subject>Adult</subject><subject>Aged</subject><subject>Blood Pressure</subject><subject>Clinical Trials as Topic</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Ethanolamines - administration & dosage</subject><subject>Female</subject><subject>Furosemide - administration & dosage</subject><subject>Humans</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - drug therapy</subject><subject>Labetalol - administration & dosage</subject><subject>Labetalol - adverse effects</subject><subject>Male</subject><subject>Methyldopa - administration & dosage</subject><subject>Methyldopa - adverse effects</subject><subject>Middle Aged</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UdtKxDAQDaLoevkDhTwqbHXStOnWB0HEGywIsj6HNJm6kbQpSVbZv_CT7briywwz53BmOIeQUwaXDJi4AoA8q3nBz2f8ogZWQFbtkAkryzKrmMh3yeSfckAOY_wYR6hLsU_2BS9FDXxCvhcBVeqwT9S3NOInBqTL9YAhYR-t7-mXTUvqVINJOe-o9t2gAprtvsO0XDvjB0VVb2i7Cj5iZw1e01eMK5fiRlZR5_v3LGHoptT4VeMwa5ztzZR2I8fq8TwGmoJV7pjstcpFPPnrR-Tt4X5x95TNXx6f727nGeaCpUyrHIQpVK1KaFvRQAUlAstzLYoZmwmmiwKgbSrNTN6aptDA63Esa2jEWPkROdvqDqumQyOHYDsV1vLPmRG_2eI4PvFpMcioLfYajQ2okzTeSgZyk4Tc2Cw3NssZl79JyIr_AL9yfM0</recordid><startdate>19831017</startdate><enddate>19831017</enddate><creator>Wallin, J.David</creator><creator>Wilson, Daniel</creator><creator>Winer, Nathaniel</creator><creator>Maronde, Robert F.</creator><creator>Michelson, Eric L.</creator><creator>Langford, Herbert</creator><creator>Maloy, James</creator><creator>Poland, Marcia</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19831017</creationdate><title>Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial</title><author>Wallin, J.David ; Wilson, Daniel ; Winer, Nathaniel ; Maronde, Robert F. ; Michelson, Eric L. ; Langford, Herbert ; Maloy, James ; Poland, Marcia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e261t-ca206d4a9a50ff6b0705e0122c6481861c4400fb7c1d2fdb4c039fb7590b67593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Blood Pressure</topic><topic>Clinical Trials as Topic</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Ethanolamines - administration & dosage</topic><topic>Female</topic><topic>Furosemide - administration & dosage</topic><topic>Humans</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - drug therapy</topic><topic>Labetalol - administration & dosage</topic><topic>Labetalol - adverse effects</topic><topic>Male</topic><topic>Methyldopa - administration & dosage</topic><topic>Methyldopa - adverse effects</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wallin, J.David</creatorcontrib><creatorcontrib>Wilson, Daniel</creatorcontrib><creatorcontrib>Winer, Nathaniel</creatorcontrib><creatorcontrib>Maronde, Robert F.</creatorcontrib><creatorcontrib>Michelson, Eric L.</creatorcontrib><creatorcontrib>Langford, Herbert</creatorcontrib><creatorcontrib>Maloy, James</creatorcontrib><creatorcontrib>Poland, Marcia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wallin, J.David</au><au>Wilson, Daniel</au><au>Winer, Nathaniel</au><au>Maronde, Robert F.</au><au>Michelson, Eric L.</au><au>Langford, Herbert</au><au>Maloy, James</au><au>Poland, Marcia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1983-10-17</date><risdate>1983</risdate><volume>75</volume><issue>4</issue><spage>87</spage><epage>94</epage><pages>87-94</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><abstract>Eighty-one severely hypertensive patients were enrolled in a multicenter, double-blind, parallel group study evaluating the efficacy and safety of labetalol alone or in combination with furosemide versus methyldopa in combination with furosemide. A one day to four week placebo lead-in phase was followed by a one- to six-week titration period and a one-year maintenance period. Treatment with labetalol alone or in combination with furosemide, as well as methyldopa plus furosemide, was associated with significant reductions in supine and standing blood pressure levels. Moreover, after six months and one year of treatment, respectively, labetalol caused a significantly (p <0.05) greater reduction in the systolic blood pressure than the methyldopa regimen. The antihypertensive effect of labetalol was associated with small, yet significant reductions in heart rate; in contrast, resting tachycardia was observed in methyldopa-treated patients. Side effect profiles of the two treatments were different, with nausea being the most commonly reported side effect during labetalol therapy, and asthenia, somnolence, and dry mouth during methyldopa therapy. Overall, 33 of 65 (53 percent) labetalol-treated and 28 of 60 (47 percent) methyldopa-treated patients had at least a good response (that is, standing diastolic blood pressure 90 to 94 mm Hg) to therapy, including 26 (40 percent) and 22 (37 percent) patients, respectively, who had standing diastolic blood pressure levels of less than 90 mm Hg. Thus, labetalol is a potentially safe and effective agent in the long-term management of the patient with severe hypertension.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>6356903</pmid><doi>10.1016/0002-9343(83)90140-7</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9343 |
| ispartof | The American journal of medicine, 1983-10, Vol.75 (4), p.87-94 |
| issn | 0002-9343 1555-7162 |
| language | eng |
| recordid | cdi_pubmed_primary_6356903 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Blood Pressure Clinical Trials as Topic Double-Blind Method Drug Therapy, Combination Ethanolamines - administration & dosage Female Furosemide - administration & dosage Humans Hypertension - diagnosis Hypertension - drug therapy Labetalol - administration & dosage Labetalol - adverse effects Male Methyldopa - administration & dosage Methyldopa - adverse effects Middle Aged |
| title | Treatment of severe hypertension with labetalol compared with methyldopa and furosemide: Results of a long-term, double-blind, multicenter trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T11%3A54%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20severe%20hypertension%20with%20labetalol%20compared%20with%20methyldopa%20and%20furosemide:%20Results%20of%20a%20long-term,%20double-blind,%20multicenter%20trial&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Wallin,%20J.David&rft.date=1983-10-17&rft.volume=75&rft.issue=4&rft.spage=87&rft.epage=94&rft.pages=87-94&rft.issn=0002-9343&rft.eissn=1555-7162&rft_id=info:doi/10.1016/0002-9343(83)90140-7&rft_dat=%3Celsevier_pubme%3E0002934383901407%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6356903&rft_els_id=0002934383901407&rfr_iscdi=true |